Haemonetics Corporation (HAE) — Financial statements
Income statement, balance sheet, and cash flow for Haemonetics Corporation — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1,334↓2.0% | 1,361↑4.0% | 1,309↑12.0% | 1,169↑17.7% | 993 | |
| Cost of Revenue | 590↑1.4% | 582↓2.5% | 597↑9.4% | 546↑18.0% | 462 | |
| Gross Profit | 744↓4.5% | 779↑9.4% | 712↑14.3% | 623↑17.4% | 531 | |
| Operating Expenses | ||||||
| R&D Expenses | 60↓13.9% | 69↑10.1% | 63↑7.5% | 59↑6.2% | 55 | |
| General & Administrative Expenses | 0.00↓100.0% | 414↑0.2% | 414↑12.8% | 367↑11.9% | 328 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 8↑8.5% | 7↓1.4% | 7↑63.6% | 4 | |
| SG&A Expenses | 442↑4.8% | 422↑0.3% | 421↑12.5% | 374↑12.6% | 332 | |
| Other Expenses | 0.00↓100.0% | 65↑3.3% | 63↑84.4% | 34↓45.3% | 63 | |
| Operating Expenses | 502↓9.8% | 557↑1.8% | 547↑17.2% | 467↑3.7% | 450 | |
| Total Costs & Expenses | 1,093↓4.1% | 1,139↓0.5% | 1,144↑13.0% | 1,013↑11.0% | 912 | |
| Operating Results | ||||||
| Operating Income | 241↑8.8% | 222↑34.5% | 165↑5.7% | 156↑93.2% | 81 | |
| Depreciation & Amortization | 156↑43.0% | 109↑22.9% | 89↑4.5% | 85↓2.0% | 87 | |
| EBITDA | 397↑11.6% | 356↑20.5% | 295↑17.2% | 252↑31.4% | 192 | |
| EBIT | 241↓2.3% | 247↑19.5% | 207↑23.7% | 167↑59.0% | 105 | |
| Interest & Other Income | ||||||
| Net Interest Income | -29↓194.5% | -10↑25.1% | -13↑11.0% | -15↑14.5% | -17 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 29↑194.5% | 10↓25.1% | 13↓11.0% | 15↓14.5% | 17 | |
| Non-Operating Income | 0.00↑100.0% | -25↑39.7% | -42↓275.7% | -11↑54.3% | -24 | |
| Other Income / Expenses | -113↓1063.3% | -10↑25.1% | -13↑11.0% | -15↑14.5% | -17 | |
| Income Before Tax | 128↓39.6% | 212↑39.6% | 152↑7.4% | 141↑122.2% | 64 | |
| Income Tax Expense | 31↓30.8% | 44↑29.4% | 34↑31.9% | 26↑28.4% | 20 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 97↓42.0% | 168↑42.6% | 118↑1.9% | 115↑166.1% | 43 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 97↓42.0% | 168↑42.6% | 118↑1.9% | 115↑166.1% | 43 | |
| Bottom-Line Net Income | 97↓42.0% | 168↑42.6% | 118↑1.9% | 115↑166.1% | 43 | |
| EPS (Basic) | 2.05↓38.1% | 3.31↑42.7% | 2.32↑2.2% | 2.27↑167.1% | 0.85 | |
| EPS (Diluted) | 2.05↓38.1% | 3.31↑44.5% | 2.29↑2.2% | 2.24↑166.7% | 0.84 | |
| Weighted Average Shares | 47↓6.3% | 50↓0.7% | 51↓0.2% | 51↓0.5% | 51 | |
| Weighted Average Diluted Shares | 47↓6.7% | 51↓1.3% | 51↓0.0% | 51↑0.1% | 51 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.